Foghorn Therapeutics (FHTX) Net Cash Flow (2019 - 2026)

Foghorn Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 21.81% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $28.2 million, a 254.6% increase from a year earlier, with the FY2025 full-year figure at $27.0 million, up 208.37% from the prior year.
• Net Cash Flow grew to $6.8 million in Q1 2026 per FHTX's latest filing, from -$8.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $112.5 million in Q1 2022 and bottomed at -$152.4 million in Q2 2022.
• The 5-year median for Net Cash Flow is $6.8 million (2026), against an average of -$703294.1.
• Biggest YoY gain for Net Cash Flow was 745.28% in 2024; the steepest drop was 744.84% in 2024.
• Year by year, Net Cash Flow stood at -$35.4 million in 2022, then soared by 128.32% to $10.0 million in 2023, then slumped by 122.17% to -$2.2 million in 2024, then slumped by 280.31% to -$8.5 million in 2025, then surged by 180.24% to $6.8 million in 2026.
• Per Business Quant, the three latest FHTX Net Cash Flow figures stand at $6.8 million (Q1 2026), -$8.5 million (Q4 2025), and $16.8 million (Q3 2025).